Table 2

Univariate and multivariate Cox regression analysis (5-year relapse-free survival) of the 13-gene prognostic signature and clinical factors in stage II colorectal samples from the test series and validation series I and II

Parameters	No. of patients	Univariate^*		Multivariate^†
Parameters	No. of patients	p Value^‡	HR (95% CI)	p Value^‡	HR (95% CI)
Training series (n=44)
Prognostic signature
Low risk (ref)/high risk	37/7	<0.001	18.2 (4.5 to 74.1)	<0.001	24.6 (5.4 to 111.5)
Age
Continuous	44	0.16	1.0 (0.9 to 1.0)	0.06	0.9 (0.9 to 1.0)
Gender
Female (ref)/male	30/14	0.74	1.3 (0.3 to 5.1)
Tumour localisation
Colon(ref)/rectum	40/4
No. of lymph nodes examined
n<12 (ref)/n≥12	5/39	0.99	1.0 (0.1 to 8.2)
Microsatellite instability
Unstable (ref)/stable	9/35	0.44	2.3 (0.3 to 18.3)
Adjuvant therapy
No (ref)/yes	40/4
Validation series I (n=52)
Prognostic signature
Low risk (ref)/high risk	45/7	0.02	3.6 (1.3 to 10.1)	0.001	6.4 (2.1 to 19.6)
Age
Continuous	52	0.07	1.0 (1.0 to 1.1)	0.01	1.1 (1.0 to 1.1)
Gender
Female (ref)/male	30/22	0.68	1.2 (0.5 to 3.0)
Tumour localisation
Colon (ref)/rectum	32/20	0.75	0.9 (0.3 to 2.2)
Microsatellite instability
Unstable (ref)/stable/NA	2/49/1
Validation series II (n=108)
Prognostic signature
Low risk (ref)/high risk	91/17	0.001	6.5 (2.2 to 19.7)	0.004	5.1 (1.7 to 15.5)
Age
Continuous	108	0.20	1.0 (0.9 to 1.0)
Gender
Female (ref)/male	48/60	0.65	0.8 (0.3 to 2.3)
Tumour localisation
Colon (ref)/rectum	96/12	0.15	2.6 (0.7 to 9.4)
Adjuvant therapy
No (ref)/yes/NA	72/22/14	0.02	3.7 (1.3 to 11.1)	0.04	3.3 (1.1 to 9.9)

↵* p Values and HR were not calculated when there were <5 samples in either of the groups.
↵† Validation series I: n=51; validation series II: n=94.
↵‡ p Values calculated from Wald statistics; statistically significant p values (<0.05) in bold.
NA, information not available; ref, reference group in calculation of HR.